17 Jun 2020 07:00
AorTech International Plc (to be renamed RUA Life Sciences Plc)
("AorTech", the "Company" or the "Group")
Change of name and rebranding
Further to its announcement of 31 March 2020, AorTech International Plc (to be renamed RUA Life Sciences Plc), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM), confirms that the change of its name, and rebranding of all group businesses, under the RUA brand has taken effect. Accordingly, it is expected that trading on AIM in the Company's ordinary shares under the new name, RUA Life Sciences Plc, will commence at 8.00 a.m. on 18 June 2020 and at the same time the Company's TIDM will change to "RUA".
The Company's adoption of a new name follows its recent acquisition of RUA Medical Devices Limited and reflects its vision to improve the lives of millions of patients by improving and enabling medical devices with Elast-EonTM, the world's leading long-term implantable polyurethane. Whether it is licensing Elast-EonTM, manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing the Company's vision.
In addition, the Company's website address, which provides all information in compliance with AIM Rule 26, will be changed to www.rualifesciences.com, with effect from 8.00 a.m. on 18 June 2020.
Bill Brown, Chairman of the AorTech, said: "The change of name from AorTech International Plc to RUA Life Sciences Plc is an important development for the Company. The recent acquisition of RUA Medical Devices Limited which created a fully formed, end-to-end medical device business has facilitated the rebranding of all group businesses under the RUA banner. I am delighted that the newly enlarged Group is now able to move forward under a unified brand as we embark on the next phase of developing the Group's business."
For further information contact:
AorTech International plc
Bill Brown, Chairman Tel: +44 (0) 77 3071 8296
David Richmond, CEO Tel: +44 (0) 78 9999 6400
Shore Capital
Tom Griffiths/David Coaten Tel: +44 (0)20 7408 4080
About AorTech International (to be renamed RUA Life Sciences)
The RUA Life Sciences group was created in April 2020 when AorTech International plc acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.
Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-EonTM, the world's leading long-term implantable polyurethane.
Whether it is licensing Elast-EonTM, manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.
Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.
The Group's four business units are:
RUA Medical: End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.
RUA Biomaterials: Licensor of Elast-EonTM polymers to the medical device industry.
RUA Vascular: Development of large bore polymer sealed grafts and soft tissue patches.
RUA Structural Heart: Development of tri leaflet polymeric heart valves.